Cempra, Inc. to Report Second Quarter 2013 Financial and Operating Results, and Host Conference Call and Webcast on July 30,

Cempra, Inc. to Report Second Quarter 2013 Financial and Operating Results,
and Host Conference Call and Webcast on July 30, 2013

CHAPEL HILL, N.C., July 23, 2013 (GLOBE NEWSWIRE) -- Cempra, Inc.
(Nasdaq:CEMP) today announced that it will report second quarter 2013
financial results and provide a business update after the close of U.S.
financial markets on July 30, 2013.Prabhavathi Fernandes, Ph.D., president
and chief executive officer ofCempra,will host a conference call and webcast
at4:30 p.m. EDT,July 30, 2013.

The conference call may be accessed by dialing 877-377-7553 for domestic
callers and 253-237-1151 for international callers. Please specify to the
operator that you would like to join the "Cempra, Inc., Second Quarter 2013
Financial Results Call, conference ID#: 16263207." The conference call will be
webcast live under the investor relations section ofCempra's website
atwww.cempra.com, and will be archived there for 30 days following the call.
Please visitCempra's website several minutes prior to the start of the
broadcast to ensure adequate time for any software download that may be

AboutCempra, Inc.

Founded in 2006, Cempra, Inc. is a clinical-stage pharmaceutical company
focused on developing antibiotics to meet critical medical needs in the
treatment of bacterial infectious diseases. Cempra's two lead product
candidates are currently in advanced clinical development. Solithromycin
(CEM-101) is in a Phase 3 clinical trial for community-acquired bacterial
pneumonia (CABP) and is licensed to strategic commercial partner Toyama
Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain
exclusive rights in Japan. TAKSTA™ (CEM-102) is Cempra's second product
candidate, which is currently in a Phase 2 clinical trial for prosthetic joint
infections. Both seek to address the need for new treatments targeting
drug-resistant bacterial infections in the hospital and in the community. The
company also intends to use its series of proprietary lead compounds from its
novel macrolide library for uses such as the treatment of chronic inflammatory
diseases, endocrine diseases and gastric motility disorders. Additional
information about Cempra can be found at www.cempra.com.

CONTACT: Investor and Media Contacts:
         Robert E. Flamm, Ph.D.
         Russo Partners, LLC
         (212) 845-4226
         Andreas Marathovouniotis
         Russo Partners, LLC
         (212) 845-4235
Press spacebar to pause and continue. Press esc to stop.